key: cord-0257123-snutv1im
authors: See, Stephanie K.; Chen, Merissa; Bax, Sophie; Tian, Ruilin; Woerman, Amanda; Tse, Eric; Johnson, Isabel E.; Nowotny, Carlos; Muñoz, Elise N.; Sengstack, Janine; Southworth, Daniel R.; Gestwicki, Jason E.; Leonetti, Manuel D.; Kampmann, Martin
title: PIKfyve inhibition blocks endolysosomal escape of α-synuclein fibrils and spread of α-synuclein aggregation
date: 2021-01-22
journal: bioRxiv
DOI: 10.1101/2021.01.21.427704
sha: 83c00812dd42e3d1c88de05f4de25db28829aa2c
doc_id: 257123
cord_uid: snutv1im

The inter-cellular prion-like propagation of α-synuclein aggregation is emerging as an important mechanism driving the progression of neurodegenerative diseases including Parkinson’s disease and multiple system atrophy (MSA). To discover therapeutic strategies reducing the spread of α-synuclein aggregation, we performed a genome-wide CRISPR interference screen in a human cell-based model. We discovered that inhibiting PIKfyve dramatically reduced α-synuclein aggregation induced with both recombinant α-synuclein fibrils and fibrils isolated from MSA patient brain. While PIKfyve inhibition did not affect fibril uptake or α-synuclein clearance or secretion, it reduced α-synuclein trafficking from the early endosome to the lysosome, thereby limiting fibril escape from the lysosome and reducing the amount of fibrils that reach cytosolic α-synuclein to induce aggregation. These findings point to the endolysosomal transport of fibrils as a critical step in the propagation of α-synuclein aggregation and a potential therapeutic target.

Cell-based model of prion-like propagation of α-synuclein aggregation 94 95

In order to identify cellular factors that control the prion-like propagation of α-synuclein 96 aggregation (Fig. 1A) , we established a cell-based model with a FRET readout. A similar FRET-97 based model had been previously developed by the Diamond Lab to monitor aggregation by 98 microscopy and flow cytometry. 9 Given the different aggregation propensities of wild-type α-99 synuclein and the Parkinson's disease-associated A53T and E46K point mutations, we generated 100 three versions of this cell-based system: wild-type, A53T and E46K. 101

First, we generated recombinant α-synuclein fibrils to serve as aggregation seeds. We 102 purified monomeric human α-synuclein from Escherichia coli and induced fibrillization by 103 vigorous agitation at 37 ºC. We verified the generation of amyloid fibrils by the increase in 104

Thioflavin T fluorescence (Fig. 1B) and negative stain EM (Fig. 1C) . These fibrils were 105 subsequently sonicated into smaller seeds. 106

Next, we co-expressed two versions of full-length human α-synuclein fused to the 107 fluorescent proteins mClover2 and mRuby2, respectively, in HEK293T cells. We reasoned that 108 upon triggering aggregation with α-synuclein fibrils added to the cells, the monomeric fusion 109 proteins would come within close proximity to each other and generate a detectable FRET signal 110 (Fig. 1D) . 111 Fluorescent constructs were stably introduced to HEK293T cells by lentivirus. We then 112 selected monoclonal lines based on high expression of the fusion proteins and dynamic range of 113 the FRET signal. In the absence of fibrils, these reporter cells showed diffuse intracellular 114 fluorescence without visible aggregates when monitored by fluorescence microscopy (Fig. 1E ) 115 and appeared as a single population when FRET levels were monitored by flow cytometry (Fig. 116 1F). Upon exposure to recombinant α-synuclein fibrils complexed with lipofectamine, we 117 observed that the fluorescent reporter constructs formed visible puncta by fluorescent 118 microscopy ( Fig. 1E) , and a second distinct FRET-positive population of cells emerged by flow 119 cytometry (Fig. 1F) , indicating aggregation of the intracellular α-synuclein constructs. We found 120 that all three fibril types triggered aggregation in a dose-dependent manner when added to cell 121 types expressing the reporters with the corresponding sequences (WT, A53T or E46K), as 122 quantified by the percentage of FRET-positive cells (Fig. 1G) . The E46K α-synuclein FRET 123

reporter line reproducibly generated the highest percentage of FRET-positive cells, and 124 generated detergent and urea resistant aggregates (Fig. 1H) , making it an ideal cell line to use in 125 a genome-wide genetic screen to identify cellular factors controlling α-synuclein aggregation. 126 127

Genome-wide screen for modifiers of prion-like propagation of α-synuclein aggregation 128 129

To enable a genetic screen for modifiers of propagation of α-synuclein aggregation, the 130 cell lines described above also expressed catalytically inactive The screening strategy is illustrated in Figure 2A . We transduced these cells with pooled  135  lentiviral libraries containing sgRNAs targeting every protein-coding gene in the genome and  136 nontargeting control sgRNAs. Cells transduced with sgRNAs were exposed to recombinant α-137 synuclein fibrils at concentrations that yielded the half-maximal percentage of FRET-positive 138 cells, thereby maximizing the dynamic range for detecting cellular factors that either increase or 139 decrease α-synuclein aggregation. FRET-negative and FRET-positive cell populations were 140 separated by FACS. Sufficient numbers of cells were collected from each population to achieve 141 at least 500x average representation of cells per sgRNA elements in the library. Genomic DNA 142 was isolated, sgRNAs were PCR-amplified, and frequencies for each sgRNA in each population 143

were quantified by next-generation sequencing. We evaluated the effect of gene knockdown on 144 the formation of α-synuclein aggregates using our previously described bioinformatics 145

pipeline. 18,21-23 146

The genome-wide screen uncovered genes knockdown of which either increased or 147 decreased α-synuclein aggregation ( Table S1 ). Many of the top hits could be assigned to one of 148 the following biological categories: Endolysosomal system / vesicular trafficking, cytoskeleton, 149 gene expression, mitochondria, nucleocytosolic transport (Fig. 2B , Table S1 ). 150

Next, we selected hits from the primary genome-wide screen, which was performed with 151 the α-synuclein (E46K) FRET-reporter, for further characterization in secondary screens. These 152 hits were first selected from genes with an FDR < 0.1 and further narrowed to exclude heavily 153 redundant genes specific to a biological pathway, resulting in a focused library targeting 249 154 genes (Table S2) . Using this focused library, we conducted secondary screens with all three 155

versions of the α-synuclein reporter. The hits targeted by this focused retest library revalidated in 156 all three cell lines robustly with minimal differences between the α-synuclein variants (Fig. 3A,  157 Fig. S1, Table S2 ).

Genes that reproduced strongly in the WT, A53T, and E46K cell lines are displayed in 159 Figure 3B , grouped by their biological pathways. The knockdown of many genes in the 160 endolysosomal system dramatically reduced aggregation. One major pathway stood out for its 161 strong impact on α-synuclein aggregation: the phosphatidylinositol pathway, a major signaling 162 pathway that regulates, among other processes, endolysosomal trafficking and autophagy. We 163 decided to prioritize this pathway for further characterization because knockdown of several 164 factors in this pathway robustly reduced aggregation, making it a potential therapeutic target. 165 166 167

Pharmacological inhibition of PIKfyve and other phosphatidylinositol kinases reduces α-168 synuclein aggregation 169 170

In order to comprehensively test which members of the phosphatidylinositol pathway 171 control aggregation, we selected a panel of small molecule inhibitors of major kinases involved 172 in this pathway (Fig. 4A, Fig. S2) . Interestingly, the majority of these inhibitors blocked 173 aggregation robustly (Fig. 4A) . In particular, apilimod, an inhibitor of PI-3P-5-kinase (PIKfyve), 174

which phosphorylates the D-5 position in phosphatidylinositol-3-phosphate (PI3P) to yield 175 phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2), 24 dramatically reduced aggregation with IC50 176 values below 25 nM (Fig. 4B) . To confirm these results genetically, we cloned two individual 177 sgRNAs each targeting PIKfyve and validated that PIKfyve knockdown in our FRET reporter 178 lines also reduced aggregation (Fig. 4C, Table S2 ) but to a lesser extent compared to the 179 pharmacological inhibitors. PIKfyve inhibition also reduced the amount of insoluble α-synuclein, 180 measured by a filter trap assay, in a dose-dependent manner (Fig. 4D,E) . 181 Recently, α-synuclein fibrils isolated from post-mortem brains from patients with a 182 synucleinopathy called multiple system atrophy (MSA) were shown to trigger aggregation in 183 cellular and mouse models of α-synuclein propagation. 6, 9, 10 We tested the effect of PIKFyve 184 inhibition on α-synuclein aggregation triggered by α-synuclein fibrils isolated from deceased 185 MSA patient brain samples. We found that PIKYVE inhibition decreased α-synuclein 186 aggregation in our FRET reporter line seeded with patient brain-derived α-synuclein by flow 187 cytometry (Fig. 4F) .

PIKfyve inhibition does not increase autophagic flux, α-synuclein secretion, nor decrease 190 fibril uptake 191 192

We next investigated the mechanism by which PIKfyve inhibition reduces α-synuclein 193 aggregation. Given the importance of autophagy for the clearance of aggregated proteins, 194

including α-synuclein, 25 we hypothesized that PIKfyve might reduce aggregation by increasing 195 autophagic flux. We first evaluated the effect of PIKfyve inhibition on autophagy using a LC3 196

cell-based reporter. This reporter consists of a fusion construct of GFP-LC3 and RFP-LC3DG 197 that is cleaved by ATG4 during autophagy. GFP-LC3 is degraded by autophagy whereas LC3DG remains in the cytosol as an internal control. Autophagic flux can then be quantified by 199 flow cytometry as the ratio of RFP to GFP. 26 Surprisingly, we discovered that PIKfyve inhibition 200 decreased, rather than increased autophagic flux (Fig. 5A) in the presence of torin, a 201 pharmacological activator of autophagy. 202

Previous studies have suggested that the inhibition of autophagy can promote the 203 exocytosis of α-synuclein as an alternative clearance mechanism. 27 We therefore hypothesized 204 that PIKfyve inhibition may lower levels of aggregated α-synuclein by promoting export of 205 intracellular α-synuclein. To test this hypothesis, we performed an ELISA to detect the level of 206 α-synuclein-Clover in the cell culture media after triggering aggregation (Fig. 5B) . PIKfyve 207 inhibition did not cause an increase in the amount of α-synuclein-Clover in the media, and there 208 was no decrease in intracellular α-synuclein-Clover levels ( Fig. 5C) , suggesting that an export 209 mechanism could not explain the dramatic decrease in aggregation during PIKfyve inhibition. 210 We then evaluated if PIKFyve inhibition reduced aggregation by blocking the initial fibril 211 uptake into cells. By measuring the uptake of fluorescently tagged fibrils at different apilimod 212

concentrations, we determined that PIKFyve inhibition did not alter fibril uptake (Fig. 5D ).

PIKfyve inhibition interferes with α-synuclein fibril trafficking to the lysosome and 215 lysosomal rupture 216 217

Given the role of PIKfyve at multiple stages of the endolysosomal pathway, 28 we sought 218

to investigate if PIKfyve inhibition could alter fibril trafficking. We monitored fibril transport in 219 relationship to the early endosome marker EEA1 (Fig. 6A ) and the late endosome/lysosome 220 marker LAMP1 (Fig. 6B ) at 30 min, 1 h, 2h, 4h, and 24 h after fibril exposure. In the absence of 221

PIKfyve inhibition, fibrils are not detected in EEA1-positive compartments at these time points 222 (Fig. 6A) , but accumulate in LAMP1-positive compartments as early as 30 min after fibril 223 exposure (Fig. 6B) . In the presence of apilimod, which resulted in enlargement of both EEA1 224 and LAMP1 vesicles, fibrils colocalized with EEA1 vesicles at the 1-hour timepoint, 225

dramatically reducing the number of fibrils that reach LAMP1 vesicles at early and late 226 timepoints. These results suggest that PIKfyve inhibition reduces fibril trafficking from the early 227 to late endosome/lysosome. 228

α-synuclein fibrils have been previously shown to cause endolysosomal damage, 29 229 leading us to hypothesize that PIKFyve inhibition may reduce α-synuclein aggregation by 230 reducing fibril-induced rupture of the lysosome and subsequent escape of fibrils to the cytosol. 231 We tested this hypothesis by monitoring the formation lysosomal damage using a cytosolic GFP 232 fusion of galectin 3 (GAL3), a lectin that binds b-galactosides and forms puncta when these 233 sugars are exposed on damaged endolysosomes. 30 Consistent with previously reported studies 29 234 α-synuclein fibrils caused endolysomal damage. Pharmacological and genetic PIKFyve 235 inhibition dramatically reduced α-synuclein fibril-induced endolysomal damage ( Fig. 7A-C) . 236 Given the strong reduction of lysosomal damage upon PIKFYVE inhibition, we asked 237

whether PIKFyve inhibition generally protects lysosomes from damage, or whether the effect is 238 specific to damage induced by α-synuclein fibrils. To address this question, we treated cells with 239 leucyl-leucyl-O-methyl ester (LLOME), a compound that accumulates in the lumen of acidified 240 organelles, rapidly forms membranolytic polymers after cleavage by cathepsin C, 30,31 thereby 241 causing direct lysosomal rupture. We confirmed that LLOME damages endolysosomal 242 membranes in our cell line using the GAL3-GFP reporter (Fig. 7D) . Apilimod did not protect 243 cells from LLOME-induced lysosomal damage, but rather sensitized them (Fig. 7D) , indicating 244 that its protective effect in the presence of α-synuclein fibrils is due to inhibition of fibrils 245 reaching the lysosome, as opposed to a direct effect on lysosomal integrity. 246

These results together suggest that PIKfyve controls fibril trafficking from the early to 247 late endosome, and that the inhibition of PIKfyve decreases the amount of fibrils reaching 248

lysosomes. The resulting lysosomal rupture limits fibrils from templating aggregation of soluble 249 α-synuclein in the cytosol, inhibiting α-synuclein aggregate spreading (Fig. 8) Our genome-wide screen also pointed to additional pathways relevant for prion-like 273

propagation of α-synuclein aggregation, including other trafficking factors, such as the 274

Parkinson's risk gene DNAJC13. Another major class of hits is related to gene expression 275 (including translation and ribosome biogenesis). These hits, however, may be pleiotropic as they 276 likely affect expression of many genes. 277 We had expected to discover a larger network of molecular chaperones that regulate α- α-synuclein fibrils were negatively stained with 0.75% uranyl formate (pH 5.5-6.0) on 341 thin amorphous carbon-layered 400-mesh copper grids (Pelco Cat# 1GC400). 5 µl of 5 mg/mL 342 fibrils was applied to the grid for 1 min before removing the droplet with Whatman paper, 343 followed by two washes with 5 µl of ddH2O and two applications of 5 µl of uranyl formate 344 removed by vacuum. Grids were imaged at room temperature using a Fei Tecnai 12 microscope 345 operating at 120 kV. Images of WT and A53T fibrils were captured on a US 4000 CCD camera 346 at x44117 resulting in a sampling of 3.4 Å/pixel. E46K fibrils were imaged on the microscope at 347 x57692 resulting in a sampling of 2.6 Å/pixel. 348 349

Plasmid and library design 350 351

Plasmids for the FRET-aggregation reporters were generated by subcloning full length 352 human α-synuclein PCR-amplified from pCAGGS-aSyn-CFP (a gift from Robert Edwards and 353

Ken Nakamura) 39 The GFP-LC3-RFP-LC3ΔG reporter line was generated as follows: HEK293T cells 408

stably expressing dCas9-BFP-KRAB was transduced with pRT48 and a monoclonal line was 409 selected for a high dynamic range for autophagic flux and high CRISPRi activity. 410 411

Primary CRISPRi genome-wide screen 412 413

The genome-wide screen was carried out as seven parallel screens with sublibraries H1-414

H7. 40 For each sublibrary, 100 million HEK293T cells were seeded into a 15 cm 2 plate with 415 complete DMEM and transfected with 5 µg of lentiviral plasmid packaging mix and 5 µg of 416 pooled sgRNA library plasmid using lipofectamine 2000 (ThermoFisher Cat# 11668019) and 417 incubated for 2 days. 418

Lentivirus-containing media was removed and filter sterilized using a Millex-GV syringe 419 filter unit (Millipore Cat# SLGV033RB). For each library, 80 million FRET reporter cells were 420

infected with filtered lentivirus-containing media for a target MOI of ~30-70%. Infected cells 421

were selected with puromycin (1 ng/µL) for three days until % BFP >95%. Puromycin selected 422 cells were then seeded at 25,000 cells/ well into fifty 96-well plates (ThermoFisher Cat#  423 12556008) with 0.25 ug/mL fibrils and 0.002% (v/v) lipofectamine. After 24 hours, cells were 424 removed from the plates and sorted into FRET negative and FRET positive populations. 425

Genomic DNA was isolated using the Macherey-Nagel Blood L kit (Machery-Nagel Cat# 426 740954.20) according to the manufacturer's protocol. SgRNA-encoding cassettes were then 427 amplified by PCR, purified using SPRI-select beads, and deep-sequenced as previously 428

published. 23 Phenotypes and P values for each gene were generated using the following pipeline: 429

(https://kampmannlab.ucsf.edu/mageck-inc). 23 430 431

Microscopy and Flow cytometry secondary assays 432 433

To monitor α-synuclein aggregation, FRET reporter cells were seeded (25,000 cells/well) 434

into 70 µL per well in a 96 well plates. In each well, 3 µL 0.25 mg/mL fibrils were complexed 435 with 0.2 µL Lipofectamine 2000 for 1 hour at room temperature and added to 27 µL Optimem 436 (ThermoFisher Cat# 31985070). The complex in Optimem was then added to pre-seeded reporter 437 cells in 96-well plates and analyzed 24 hours after seeding. For analysis, cells were stained with 438

Hoechst 33342 (ThermoFisher Cat# 5553141) at 0.5 µg/mL and analyzed by flow cytometry 439 using a BD FACSCelesta or by fluorescence microscopy using an InCell 6000 (GE Cat# 28-440 9938-51). Cells with sgRNA knockdown were similarly analyzed using a comparable protocol 5 441 days after transduction with individual sgRNA-encoding lentivirus. 442

To monitor fibril uptake, CRISPRi-HEK293T cells were seeded (25,000 cells/well) into 443 70 µL in a 96-well plate with 3 µL of 0.25 mg/mL fibrils complexed with 0. GAPDH as an internal loading control. sgRNA activity is expressed as knockdown efficiency. 513 qPCR results and primer sequences are provided in Table S2 . We thank Ana Maria Cuervo, Robert Edwards, Matt Jacobson, Carmen Nussbaum, Xiaoyan 527

Guo, Nina Dräger, Emmy Li, Kun Leng, and other members of the Kampmann Lab for helpful 528 discussions on experimental design and interpretation. We thank all co-authors, Avi Samelson, 529

and Xiaoyan Guo for discussions and feedback on the manuscript. We thank Eric Chow and 530

Derek 

Self-propagation of pathogenic protein aggregates in Biology and Medicine

CRISPR-mediated modular RNA-guided regulation of transcription 587 in eukaryotes

Integrated platform for genome-wide 589 screening and construction of high-density genetic interaction maps in mammalian cells

Functional genomics platform for 592 pooled screening and generation of mammalian genetic interaction maps

PIKfyve, a mammalian ortholog of yeast 597 Fab1p lipid kinase, synthesizes 5-phosphoinositides. Effect of insulin

& Rubinsztein, D. C. α-synuclein Is 600 Degraded by Both Autophagy and the Proteasome

Autophagic failure promotes the exocytosis and intercellular transfer of α-605 synuclein

Impaired endo-lysosomal 609 membrane integrity accelerates the seeding progression of α-synuclein aggregates

Mechanism of L-leucyl-L-leucine methyl ester-mediated 614 killing of cytotoxic lymphocytes: Dependence on a lysosomal thiol protease, dipeptidyl 615 peptidase I, that is enriched in these cells

Small molecule inhibition of PIKFYVE kinase rescues gain-and loss-618 of-function C9ORF72 ALS/FTD disease processes in vivo

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and 621 SARS-CoV-2

Molecular dissection of amyloid disaggregation by human HSP70

Modulation of neurodegeneration by molecular 625 chaperones

Pathological α-synuclein transmission initiated by binding lymphocyte-627 activation gene 3. Science (80-. )

Eight prion strains have PrP(Sc) molecules with different conformations

Mechanism of scrapie prion precipitation with phosphotungstate 631 anions

Lipid rafts mediate the synaptic localization of α-synuclein

Compact and highly active next-generation libraries for CRISPR-635 mediated gene repression and activation

Compromised function of the ESCRT pathway promotes endolysosomal 637 escape of tau seeds and propagation of tau aggregation

Improved split fluorescent proteins for endogenous protein labeling

Error bars represent mean ± S.E.M from n = 4 technical 650 replicates. (C) Representative negative stain electron micrographs α-synuclein fibrils formed from 651 recombinant protein with the WT sequence or the Parkinson's Disease-associated mutations A53T or

Exposure to α-synuclein fibrils induces aggregation of the reporter. During aggregation, the 655 proximity of the fluorescently tagged α-synuclein can be detected by fluorescence microscopy or by flow 656 cytometry. (E) Representative fluorescence microscopy images of reporter cells exposed to α-synuclein 657 fibrils or lipofectamine alone

G) Quantification of % 660 FRET-positive cells using flow cytometry across concentration ranges of α-synuclein fibrils. Error bars 661 represent mean ± S.E.M from n = 3 technical replicates. (H) E46K FRET-reporter cells exposed to E46K 662 fibrils were passed through a 0.45 µm nitrocellulose membrane after lysis and 10 min incubation in either 663 TBS or 4M Urea

Infected cells were then selected, expanded 672 and exposed to α-synuclein fibrils. 24 hours later, cells were sorted into FRET-negative and FRET-673 positive populations by FACS. sgRNA-encoding cassettes were amplified from the genomic DNA of 674 each population and sgRNA frequencies were quantified by next generation sequencing in order to 675 identify genes that control α-synuclein aggregation. (B) Volcano plot of genes showing categories of 676 major

Inhibition of PIKFYVE decreases α-synuclein aggregation in FRET reporter cells seeded 693 with fibrils. (A) Pharmacological inhibition of several kinases in the phosphatidylinositol pathway 694 decreases α-synuclein aggregation. FRET reporter cells were co-treated with fibrils and various 695 concentrations of each kinase inhibitor and collected for flow cytometry after 24 hours

Supplemental Figure 1). (B) Dose-dependent decrease of aggregation in FRET reporter cells treated with 697 the PIKFYVE inhibitor apilimod. Error bars represent mean ± s.e.m from n = 3 technical replicates. (C) 698 FRET reporter cells were transduced with individual sgRNAs targeting PIKFYVE or a non-targeting 699 control sgRNA (NTC) and aggregation was measured 5 days after transduction

M from n = 3 technical replicates. (D) Apilimod decreases insoluble intracellular α-synuclein

FRET-reporter cells exposed to increasing apilimod concentrations were passed through a 0

Error bars represent mean ± S.E.M from n = 3 technical 706 replicates. (F) Dose-dependent decrease of aggregation trigged with MSA patient brain-derived fibrils 707 derived with the PIKFYVE inhibitor apilimod

CRISPRi-HEK293T cells expressing mCherry-GFP-LC3 were treated with either 715 bafilomycin or apilimod in the presence and absence of torin. Changes in the ratio of GFP/mCherry was 716 monitored by flow cytometry. Error bars represent mean ± S.E.M from n = 3 technical replicates. (B) α-717 synuclein and mClover protein detected in the media by ELISA

Clover2 construct in FRET reporter cells, as quantified by flow cytometry. Error bars represent mean ±

M from n = 3 technical replicates. (D) PIKFYVE inhibition does not impact uptake of Alexa-555 721 tagged fibrils

PIKFYVE inhibition interferes with α-synuclein fibril trafficking to the lysosome

Representative fluorescence microscopy images of cells in which the early endosomal marker EEA1 (A) 727 or the lysosomal marker LAMP1 (B) were endogenously labeled with the split-mNeonGreen system and 728 exposed to fibrils tagged with Alexa555 in the presence and absence of Apilimod. Timepoints were 729 acquired at 30 min, 1 h, 2h, 4h, and 24 h after fibril addition

PIKFYVE inhibition reduces fibril-induced lysosomal rupture. (A) Representative 734 fluorescence microscopy images of CRISPRi-HEK293T cells expressing an EGFP-Galectin3

EGFP-Gal3 reporter cells were co-treated with fibrils and apilimod 736 or DMSO 24 hours prior to imaging

Error bars represent mean ± S.E.M for n = 2 technical replicates (with at least 300 nuclei 739 per image). (C) EGFP-Gal3 reporter cells were transduced with individual sgRNAs targeting PIP4K2C, 740 PIKFYVE or a non-targeting control sgRNA (NTC). 5 days after transduction fibrils were added to 741 EGFP-Gal3 reporter cells and puncta formation was observed by microscopy

technical replicates (with at least 300 nuclei per image). (D) EGFP-Gal3 reporter cells 743 were treated with various concentrations of LLOME and apilimod and 24 h after treatment puncta 744 formation was observed by microscopy

Aggregation efficiency in FRET reporter cells treated with various concentration 758 of inhibitors of phosphatidylinositol signaling pathway members